SELECT results presented at #AHA23.
In overweight or obese adults who do not have diabetes, semaglutide reduced the risk of major adverse CV events by 20%.
Watch OnDemand and gain access to 300+ sessions in 27 specialty areas with hours of CE credit.
🔗 bit.ly/3H9ifhu
